[151] Li J, Yan LN, Yang J, et al. Indicators of
prognosis after liver transplantation in Chinese hepatocellular carcinoma
patients[J]. World J Gastroenterol, 2009, 15(33):4170-6. [152] 邵卓, 杨广顺, 杨宁, 等. 三亚共识在原发性肝癌肝移植治疗中的运用[J]. 中国实用外科杂志, 2008, 28(6): 466-9. [153] Kulik L, Heimbach JK, Zaiem F, et al. Therapies
for patients with hepatocellular carcinoma awaiting liver transplantation: A
systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 381-400. [154] Lee S, Kim KW, Song GW, et al. The Real Impact
of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for
Hepatocellular Carcinoma[J]. Liver Cancer, 2020, 9(6): 721-33. [155] Mazzaferro V, Citterio D, Bhoori S, et al. Liver
transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a
randomised, controlled, phase 2b/3 trial[J]. Lancet Oncol, 2020, 21(7): 947-56.
[156] Mehta N, Guy J, Frenette CT, et al. Excellent
Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular
Carcinoma to Within Milan Criteria: A Multicenter Study[J]. Clin Gastroenterol
Hepatol, 2018, 16(6):955-64. [157] Llovet JM, Pavel M, Rimola J, et al. Pilot study
of living donor liver transplantation for patients with hepatocellular
carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended
criteria)[J]. Liver Transpl, 2018, 24(3):369-79. [158] Pinheiro RS, Waisberg DR, Nacif LS, et al.
Living donor liver transplantation for hepatocellular cancer: an (almost)
exclusive Eastern procedure?[J]. Transl Gastroenterol Hepatol, 2017, 2: 68. [159] Sposito C, Cucchetti A, Mazzaferro V. Assessing
Competing Risks for Death Following Liver Transplantation for Hepatocellular
Carcinoma[J]. Dig Dis Sci, 2019, 64(4): 1001-7. [160] Segev DL, Sozio SM, Shin EJ, et al. Steroid
avoidance in liver transplantation: meta-analysis and meta-regression of
randomized trials[J]. Liver Transpl, 2008, 14(4):512-25. [161] Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC,
et al. Reduced exposure to calcineurin inhibitors early after liver
transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol,
2013, 59(6): 1193-9. [162] Liang W, Wang D, Ling X, et al. Sirolimus-based
immunosuppression in liver transplantation for hepatocellular carcinoma: a
meta-analysis[J]. Liver Transpl, 2012, 18(1): 62-9. [163] Zhou J, Wang Z, Wu ZQ, et al. Sirolimus-based
immunosuppression therapy in liver transplantation for patients with
hepatocellular carcinoma exceeding the Milan criteria[J]. Transplant Proc,
2008, 40(10): 3548-53. [164] Geissler EK, Schnitzbauer AA, Zulke C, et al.
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A
Randomized, Multicenter, Open-Label Phase 3 Trial[J]. ransplantation, 2016, 100(1): 116-25. [165] Thorat A, Jeng LB, Yang HR, et al. Assessing the
role of everolimus in reducing hepatocellular carcinoma recurrence after living
donor liver transplantation for patients within the UCSF criteria: re-inventing
the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary
Pancreat Surg, 2017, 21(4): 205-11. [166] Schnitzbauer AA, Filmann N, Adam R, et al. mTOR
Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular
Carcinoma in Patients With Active Tumors[J]. Ann Surg, 2020, 272(5): 855-62. [167] Filgueira NA. Hepatocellular carcinoma
recurrence after liver transplantation: Risk factors, screening and clinical
presentation[J]. World J Hepatol, 2019, 11(3):261-72. [168] Au KP, Chok KSH. Multidisciplinary approach for
post-liver transplant recurrence of hepatocellular carcinoma: A proposed
management algorithm[J]. World J Gastroenterol, 2018, 24(45): 5081-94. [169] Iavarone M, Invernizzi F, Czauderna C, et al.
Preliminary experience on safety of regorafenib after sorafenib failure in
recurrent hepatocellular carcinoma after liver transplantation[J]. Am J
Transplant, 2019, 19(11): 3176-84. [170] Nordness MF, Hamel S, Godfrey CM, et al. Fatal
hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are
checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant,
2020, 20(3): 879-83. [171] Shi GM,
Wang J, Huang XW, et al. Graft Programmed Death Ligand 1 Expression as a Marker
for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors[J]. Liver Transpl,
2021, 27(3): 444-9. [172] Hasegawa K, Aoki T, Ishizawa T, et al.
Comparison of the therapeutic outcomes between surgical resection and
percutaneous ablation for small hepatocellular carcinoma[J]. Ann Surg Oncol,
2014, 21 Suppl 3: S348-55. [173] Li L, Zhang J, Liu X, et al. Clinical outcomes
of radiofrequency ablation and surgical resection for small hepatocellular
carcinoma: a meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(1): 51-8. [174] Huang J, Yan L, Cheng Z, et al. A randomized
trial comparing radiofrequency ablation and surgical resection for HCC
conforming to the Milan criteria[J]. Ann Surg, 2010, 252(6): 903-12. [175] Feng Q, Chi Y, Liu Y, et al. Efficacy and safety
of percutaneous radiofrequency ablation versus surgical resection for small
hepatocellular carcinoma: a meta-analysis of 23 studies[J]. J Cancer Res Clin
Oncol, 2015, 141(1): 1-9. [176] Chen QW, Ying HF, Gao S, et al. Radiofrequency ablation
plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma:
A systematic review and eta-analysis[J]. Clin Res Hepatol Gastroenterol, 2016,
40(3): 309-14. [177] Morimoto M, Numata K, Kondou M, et al. Midterm
outcomes in patients with intermediate-sized hepatocellular carcinoma: a
randomized controlled trial for determining the efficacy of radiofrequency
ablation combined with transcatheter arterial chemoembolization[J]. Cancer,
2010, 116(23): 5452-60. [178] Peng ZW, Zhang YJ, Chen MS, et al.
Radiofrequency ablation with or without transcatheter arterial
chemoembolization in the treatment of hepatocellular carcinoma:a prospective
randomized trial[J]. J Clin Oncol, 2013, 31(4): 426-32. [179] Wang L, Ke Q, Lin N, et al. The efficacy of
transarterial chemoembolization combined with microwave ablation for
unresectable hepatocellular carcinoma: a systematic review and
meta-analysis[J]. Int J Hyperthermia, 2019, 36(1): 1288-96. [180] Livraghi
T, Meloni F, Di Stasi M, et al. Sustained complete response and complications
rates after radiofrequency ablation of very early hepatocellular carcinoma in
cirrhosis: Is resection still the treatment of choice?[J]. Hepatology, 2008,
47(1): 82-9. [181] Peng ZW, Lin XJ, Zhang YJ, et al. Radiofrequency
ablation versus hepatic resection for the treatment of hepatocellular
carcinomas 2 cm or smaller: a retrospective comparative study[J]. Radiology,
2012, 262(3): 1022-33. [182] Vietti Violi N, Duran R, Guiu B, et al. Efficacy
of microwave ablation versus radiofrequency ablation for the treatment of
hepatocellular carcinoma in patients with chronic liver disease: a randomised
controlled phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(5): 317-25.
|
